Newsfeeds - Spark Newswire

1 minute read

FDA Suggests NRx Pharma’s Bipolar Program To Be Enlarged For Chronic Treatment Of Patients With Suicidality

Today, 5:51 PM

NRx Pharmaceuticals Inc (NASDAQ:NRXP) reported the minutes of a Type B meeting with the FDA’s Division of Psychiatry Products held…

NRXP

1 minute read

HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $2 Price Target

By Benzinga Newsdesk

Today, 5:51 PM

HC Wainwright & Co. analyst Vernon Bernardino reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $2 price target.

NRXP

1 minute read

NRx Pharmaceuticals Provided Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101; Said It Appears That NRX Pharmaceuticals Has Reached Alignment With The Fda Regarding Its Proposed Registration Manufacturing Plan.

By Charles Gross

Today, 5:51 PM

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage central nervous system (CNS) biopharmaceutical company, today announced that it had a meeting and a written response from the Food and Drug Administration (FDA) last week regarding its lead compound, NRX-101.

NRXP

1 minute read

NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients With Bipolar Depression With Acute Suicidality

By Bill Haddad

Today, 5:51 PM

First investigational drug for patients with Severe Bipolar Depression and Acute Suicidal Ideation/Behavior, a high unmet medical need Company received Breakthrough Therapy Designation and a Special Protocol

NRXP

1 minute read

NRx Pharmaceuticals Says Offering Aggregate Of Up To $20M Of Common Stock

By Michael Horton

Today, 5:51 PM

-SEC Filing

NRXP

1 minute read

News

NRx Receives Nasdaq Notice of Listing Compliance

By Benzinga Newsdesk

Today, 5:51 PM

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced it received written notice on December 1,

NRXP